An expert Chrysalis Advisory team, led by Partner Nick Northcott, were engaged by CT:IQ (collaboration of industry, clinical, academic and government partners interested in improving clinical trial impact and quality) to understand to investigate barriers to uptake of eConsent within the Australian clinical trial context and to create actionable insights to support increased adoption. In addition, gaining a greater understanding of the current use and adoption of eConsent across the Australian clinical trials landscape, including stakeholder opinions about the benefits, risks and critical success factors for eConsent implementation, provides information for those seeking to trial and ultimately implement eConsent.

The report was presented at a CT:IQ steering committee in June 2019 in Sydney at the George Institute for Global Health and officially launched at the 2019 AusBiotech Conference in Melbourne by CT:IQ Director Leanne Weekes.

In addition, Chrysalis Advisory’s Prof Nik Zeps and Nick Northcott in collaboration with CT:IQ Director Leanne Weekes were published in the Medical Journal of Australia (MJA).

Click here to download the article.

Click here to download the report for free.

Click here to download the slides from the presentation to the CT:IQ Steering Committee.


Learn more about Growth Advisory